Achillion Pharmaceuticals Inc., of New Haven, Conn., appointed Muzammil Mansuri to its scientific advisory board.
ActivX Biosciences Inc., of La Jolla, Calif., appointed J.C. MacRae executive vice president and chief financial officer.
ARC Pharmaceuticals Inc., of Vancouver, British Columbia, appointed John North to its board.
BioWisdom Ltd., of Cambridge, Mass., appointed Julie Barnes to its board.
CancerVax Corp., of Carlsbad, Calif., appointed Martin Mattingly executive vice president.
Dharmacon Inc., of Lafayette, Colo., appointed Michael Deines vice president of marketing.
Elusys Therapeutics Inc., of Pine Brook, N.J., added Laura Knipmeyer as project director.
Embrex Inc., of Research Triangle Park, N.C., will add Ron Bryant as vice president, North America, sales and service, effective June 2.
Focus Technologies, of Herndon, Va., added Robert Flamm as chief scientific liaison, bacteriology.
Friedman, Billings, Ramsey & Co. Inc., of Arlington, Va., appointed James Reddoch senior vice president and senior analyst of biotechnology research.
Immunetrics Inc., of Pittsburgh, added Ronald Herberman to its advisory board as founding member.
InforSense Ltd., of London, added Frank Jones as nonexecutive chairman.
InterMune Inc., of Brisbane, Calif., hired Fred Schreiber as senior vice president of human resources and Malcolm McKay as vice president of corporate compliance. It also promoted William Bradford to vice president of clinical research.
MGI Pharma Inc., of Minneapolis, promoted Reggie Bowerman to vice president, marketing; Nancy Evertz to vice president, finance and administration; and Kristin Gustafson to vice president, human resources.
NeoStem Inc., of Agoura Hills, Calif., named Edward Garnett to its business advisory board.
Osiris Therapeutics Inc., of Baltimore, elected Felix Gutzwiller to its board.
Proteome Sciences plc, of Surrey, UK, appointed Sandra Steiner to the board as research and development director.
TheraSense Inc., of Alameda, Calif., elected Jonathan Lord to its board.
The Toronto Biotechnology Initiative in Toronto appointed Lorne Meikle president.
Transkaryotic Therapies Inc., of Cambridge, Mass., said Douglas Treco resigned but will act as senior adviser through June 30. Michael Heartlein was promoted to vice president, research.
U.S. Bancorp Piper Jaffray in New York added Edward Tenthoff as senior research analyst.
Xerion Pharmaceuticals AG, of Martinsried, Germany, appointed Anil Singhal chief drug development officer. He will be based at Xerion Pharmaceuticals Inc. in Cambridge, Mass.